research Olumiant (Baricitinib): A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Efficacy and Safety of Ozenoxacin 1% Cream for Topical Treatment of Impetigo in Children and Adults
Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.
research Induction of Versican by Ascorbic Acid 2-Phosphate in Dermal Papilla Cells
Vitamin C derivative increases versican in cells, potentially aiding hair growth.
research Lower Urinary Tract Symptoms: What’s New in Medical Treatment?
New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
research Efficacy and Safety of Dupilumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
research Long-Term Efficacy of Baricitinib in the Treatment of Alopecia Areata: Results at Week 104 from the BRAVE-AA1 and BRAVE-AA2 Studies
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Non-Clinical Safety Evaluation and Risk Assessment of Aleglitazar, a Dual PPAR α/γ Agonist, and Its Major Human Metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Eyebrow Hair Transplantation in Frontal Fibrosing Alopecia: Warning About the Short- and Long-Term Results
Eyebrow hair transplants in patients with frontal fibrosing alopecia may look good at first but often lose the new hair after a few years.
research Abstracts
New treatments and diagnostic methods for various animal skin conditions showed promising results.
research Analyses of Patient-Reported Outcomes with Mirvetuximab Soravtansine Versus Standard Chemotherapy in the Randomized Phase III FORWARD I Study in Ovarian Cancer
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Chemical Pharmacotherapy Options for Managing Adult Acne
The conclusion is that more research is needed to better understand and treat adult acne, and that patient education and simple treatment plans are important for better results.
research Bendamustine: An Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.
research Samcyprone (Diphenylcyclopropenone Ointment) for the Treatment of Common Warts
Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
research Telogen Effluvium: A Review
Hair loss from Telogen Effluvium usually gets better within 6 months after addressing the cause.
research Pharmacological and Histochemical Screening for Hair Growth-Promoting Activity of Daucus Carota Herbal Gel
Carrot extract in gel form may help hair grow better.
research Biotechs Target Stagnant Baldness Market
New drug shows promise for better hair growth in baldness treatment.
research Methotrexate Dose Has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial
Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
research RASopathic Alopecia: Hair Changes Associated with Vemurafenib Therapy
Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
research Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
research Prostate Specific Antigen in Diagnosis of Polycystic Ovarian Syndrome: A New Insight
PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.
research Assessing the Efficacy of Deoxycholic Acid for the Treatment of Submental Fat: A Three-Dimensional Study
Deoxycholic acid effectively reduces double chin fat with temporary side effects and high patient satisfaction.
research Androgen Profiling by Liquid Chromatography–Tandem Mass Spectrometry in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women
The research found that anovulatory young women have higher androgen and hormone levels than those who ovulate, suggesting immature hormonal regulation rather than a specific condition.
research Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.